SCHEMBL17834793

SCHEMBL17834793

CCCc1ccc(-c2ccc(-c3cnc(-c4ccc(C[C@H](NC(=O)c5ccc(CC(C)C)s5)C(=O)N5CC(C(=O)O)C5)cc4)nc3)c(F)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 7/20 0.39
▸ KIFC1 Q9BW19 3/20 0.37
▸ PRSS1 P07477 4/20 0.37
▸ TMPRSS15 P98073 4/20 0.37
▸ S1PR3 Q99500 4/20 0.35
▸ S1PR4 O95977 2/20 0.35
▸ S1PR5 Q9H228 2/20 0.35
▸ PYGL P06737 1/20 0.34
▸ DPP4 P27487 1/20 0.33
▸ TMPRSS11D O60235 1/20 0.33
▸ CTRL P40313 1/20 0.33
▸ MPL P40238 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834662 0.95 KIFC1 (0.37) S1PR1KIFC1PRSS1TMPRSS15S1PR3
SCHEMBL17834917 0.94 KIFC1 (0.36) S1PR1KIFC1PRSS1TMPRSS15S1PR3
SCHEMBL17834938 0.91 KIFC1 (0.36) S1PR1KIFC1PRSS1TMPRSS15S1PR3
SCHEMBL17995175 0.90 KIFC1 (0.36) S1PR1KIFC1PRSS1TMPRSS15S1PR3
SCHEMBL17995149 0.90 S1PR1 (0.40) S1PR1S1PR3S1PR4S1PR5PYGL
SCHEMBL17834425 0.89 KIFC1 (0.38) S1PR1KIFC1PRSS1TMPRSS15S1PR3
SCHEMBL17834639 0.86 S1PR1 (0.38) S1PR1KIFC1PRSS1TMPRSS15S1PR3
SCHEMBL17825503 0.86 KIFC1 (0.36) S1PR1KIFC1PRSS1TMPRSS15S1PR4
SCHEMBL17825537 0.86 KIFC1 (0.36) S1PR1KIFC1PRSS1TMPRSS15S1PR4
SCHEMBL17995193 0.85 PYGL (0.37) S1PR1S1PR3S1PR4S1PR5PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R S1PR1 486/4885KIFC1 4738/4885PRSS1 1124/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R S1PR1 486/4885KIFC1 4738/4885PRSS1 1124/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR S1PR1 523/4885KIFC1 4749/4885PRSS1 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback